↑ 薬物リストへ　← 戻る

Glycerol    (DrugBank: Glycerol)

5 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病1
13多発性硬化症／視神経脊髄炎3
79家族性高コレステロール血症（ホモ接合体）2
316カルニチン回路異常症1
317三頭酵素欠損症1

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02046434
(ClinicalTrials.gov)		January 201423/1/2014Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the BrainPhenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From BrainParkinson's DiseaseDrug: Glycerol PhenylbutyrateUniversity of Colorado, DenverNULLActive, not recruiting21 Years80 YearsAll40Phase 1United States

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-011585-28-FR
(EUCTR)		21/10/200905/08/2009A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) relapsing-remitting multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis		Product Name: BCG20-0134
Product Code: BCG20-0134
Other descriptive name: Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate		BTG International LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		166Phase 2aGermany;Belgium;France;Spain
2EUCTR2009-011585-28-DE
(EUCTR)		08/10/200907/07/2009Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosisA randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) relapsing-remitting multiple sclerosis
MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: BCG20-0134
Product Code: BCG20-0134
Other descriptive name: Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate		BTG International LtdNULLNot RecruitingFemale: yes
Male: yes		184Phase cFrance;European Union;Spain;Belgium;Russian Federation;Germany
3EUCTR2009-011585-28-BE
(EUCTR)		28/09/200913/07/2009Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosisA randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) relapsing-remitting multiple sclerosis
MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders		Product Name: BCG20-0134
Product Code: BCG20-0134
Other descriptive name: Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate		BTG International LtdNULLNot RecruitingFemale: yes
Male: yes		184Phase 2France;European Union;Spain;Belgium;Russian Federation;Germany

79. 家族性高コレステロール血症（ホモ接合体）　［臨床試験数：128，薬物数：105（DrugBank：29），標的遺伝子数：8，標的パスウェイ数：15］
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2011-003998-28-NL
(EUCTR)		28/02/201214/11/2011Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemiaModifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) - MODE homozygous familial hypercholesterolemia
MedDRA version: 16.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Product Name: Recombinant Human Apolipoprotein A-I/Phospholipids Complex
Product Code: CER-001
Other descriptive name: recombinant human apolipoprotein A-I
Other descriptive name: sphingomyelin
Other descriptive name: 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol)		Cerenis TherapeuticsNULLNot RecruitingFemale: yes
Male: yes		30France;United States;Canada;Netherlands;Italy;United Kingdom
2EUCTR2011-003998-28-IT
(EUCTR)		16/02/201208/03/2012Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemiaModifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) - MODE Homozygous familial hypercholesterolemia
MedDRA version: 15.1;Level: SOC;Classification code 10027433;Term: Metabolism and nutrition disorders;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Product Name: Recombinant Human Apolipoprotein
Product Code: CER-001
Other descriptive name: Recombinant Human Apolipoprotein A-I
Other descriptive name: Sfingomielina
Other descriptive name: 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol)		CERENIS THERAPEUTICS SANULLNot RecruitingFemale: yes
Male: yes		30United States;Canada;Netherlands;United Kingdom;Italy

316. カルニチン回路異常症　［臨床試験数：4，薬物数：10（DrugBank：4），標的遺伝子数：2，標的パスウェイ数：9］
Searched query = "Carnitine cycle disorder", "Carnitine palmitoyltransferase I deficiency", "CPT1 deficiency", "Carnitine palmitoyltransferase II deficiency", "CPT2 deficiency", "Carnitine-acylcarnitine translocase deficiency", "CACT deficiency", "Carnitine transporter deficiency", "OCTN-2 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02517307
(ClinicalTrials.gov)		February 20162/7/2015Fatty Acid Oxidation Defects and Insulin SensitivityRole of Fatty Acid Oxidation Defects in Insulin SensitivityVery Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, MyopathicDrug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clampOregon Health and Science UniversityNULLRecruiting18 YearsN/AAll50N/AUnited States

317. 三頭酵素欠損症　［臨床試験数：3，薬物数：8（DrugBank：4），標的遺伝子数：1，標的パスウェイ数：1］
Searched query = "Trifunctional protein deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02517307
(ClinicalTrials.gov)		February 20162/7/2015Fatty Acid Oxidation Defects and Insulin SensitivityRole of Fatty Acid Oxidation Defects in Insulin SensitivityVery Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, MyopathicDrug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clampOregon Health and Science UniversityNULLRecruiting18 YearsN/AAll50N/AUnited States

先頭へ